ArticleFrontiers in medicine2026
Clinical efficacy and pregnancy outcomes of doxycycline plus medroxyprogesterone acetate therapy for chronic endometritis in women with recurrent reproductive failure: a prospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic endometritis (CE) is associated with recurrent reproductive failure (RRF), but the optimal treatment strategy remains uncertain. This study evaluated the efficacy and safety of doxycycline plus medroxyprogesterone acetate (MPA) in women with RRF and CE. Material and methods: This prospective cohort study included 330 women with RRF and CE diagnosed by CD138 immunohistochemistry. According to the treatment received, patients were classified into the doxycycline group or the doxycycline plus MPA group, with 165 women in each group. The primary outcome was the histological cure rate of CE after one treatment course. Secondary outcomes included pregnancy rate, live birth rate, pregnancy loss rate, ongoing pregnancy rate, and adverse events. Multivariable Poisson regression with robust variance was used to adjust for potential confounders. Results: In the primary efficacy population, CE cure occurred in 117 of 158 patients (74.1%) receiving doxycycline and 130 of 160 (81.2%) receiving doxycycline plus MPA [adjusted risk difference [aRD], 6.1; 95% CI, -3.2-15.4; adjusted risk ratio [aRR], 1.08; 95% CI, 0.96-1.22; Conclusion: Doxycycline plus MPA did not significantly improve the CE cure rate in women with RRF and CE, but was associated with a higher pregnancy rate without an increase in adverse events. Trial registration: This study was registered in the Chinese Clinical Trial Registry with the registration number of ChiCTR2400080514 (31/01/2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.